131406-69-4 Usage
Type of compound
Synthetic organic compound
Structural features
Nitro group (-NO2)
Pyridine ring (a six-membered aromatic ring with one nitrogen atom)
Indan-2-ol moiety (a seven-membered ring with a hydroxyl group attached to the second carbon)
Applications
Research and pharmaceutical
Biological activities
Potential, depending on the specific application and intended purpose
Safety
Handle and use with care, following all appropriate safety guidelines and regulations
Please note that this list is based on the provided material and may not be exhaustive. Further research and analysis may be required to fully understand the properties and potential uses of this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 131406-69-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,4,0 and 6 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 131406-69:
(8*1)+(7*3)+(6*1)+(5*4)+(4*0)+(3*6)+(2*6)+(1*9)=94
94 % 10 = 4
So 131406-69-4 is a valid CAS Registry Number.
InChI:InChI=1/C16H16N2O4/c1-16(2)12-7-6-10(18(21)22)9-11(12)14(15(16)20)17-8-4-3-5-13(17)19/h3-9,14-15,20H,1-2H3
131406-69-4Relevant articles and documents
Synthesis and smooth muscle relaxant activity of a new series of potassium channel activators: 3-amido-1,1-dimethylindan-2-ols
Buckle,Arch,Edge,Foster,Houge-Frydrych,Pinto,Smith,Taylor,Taylor,Tedder,Webster
, p. 919 - 926 (2007/10/02)
The synthesis of a novel series of smooth muscle relaxants which have been shown to act via the opening or activation of potassium channels is described. Compounds have been evaluated for their ability to inhibit spontaneous tone in guinea pig isolated trachealis and structure-activity relationships are discussed. One compound in particular, 1,1-dimethyl-5-nitro-3-(2-pyridon-1-yl)indan-2-ol, (16) was identified as a potent relaxant of airways smooth muscle in vitro with IC50 = 0.15 μM and was found to significantly inhibit histamine-induced dyspnoea in conscious guinea pigs when given orally 30-45 min prior to challenge.
